LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
Launched by UCB PHARMA · Sep 8, 2005
Trial Information
Current as of June 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 2-year history of Allergic Rhinitis that became symptomatic during the annual grass pollen season.
- * A skin test for grass pollens positive:
- • Have rhinitis symptoms of such severity that the mean T4SS over the baseline period must be 6.
- Exclusion Criteria:
- • Have an associated asthma requiring corticosteroid treatment,
- • Have an atopic dermatitis or an urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids,
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
UCB Clinical Trial Call Center
Study Director
UCB Pharma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials